▼ Safinamide for Parkinson's disease.
出版信息
Drug Ther Bull. 2018 May;56(5):54-57. doi: 10.1136/dtb.2018.5.0623.
PMID:29760163
Abstract
▼ Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson's disease who are experiencing motor fluctuations with levodopa. Currently there is no cure for Parkinson's disease and drugs are used to reduce motor symptoms and improve daily activities. Here, we review the evidence for this MAO-B inhibitor.
摘要
相似文献
1
▼ Safinamide for Parkinson's disease.
Drug Ther Bull. 2018 May;56(5):54-57. doi: 10.1136/dtb.2018.5.0623.
2
[Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].[沙芬酰胺作为帕金森病患者左旋多巴附加治疗的有效性和安全性：非干预性研究]
Fortschr Neurol Psychiatr. 2018 Oct;86(10):624-634. doi: 10.1055/a-0665-4667. Epub 2018 Aug 24.
3
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.甲磺酸沙芬酰胺治疗中晚期帕金森病的药代动力学药物评价。
Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):693-699. doi: 10.1080/17425255.2017.1329418.
4
Safinamide for symptoms of Parkinson's disease.沙芬酰胺用于帕金森病症状。
Drugs Today (Barc). 2015 Nov;51(11):653-9. doi: 10.1358/dot.2015.51.11.2414529.
5
Safinamide (Xadago) for Parkinson's disease.沙芬酰胺（Xadago）用于治疗帕金森病。
Med Lett Drugs Ther. 2017 Sep 11;59(1529):151-153.
6
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.甲磺酸沙芬酰胺用于治疗帕金森病的安全性和有效性。
Expert Rev Neurother. 2016;16(3):245-58. doi: 10.1586/14737175.2016.1150783. Epub 2016 Feb 19.
7
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.司来吉兰作为左旋多巴附加治疗中晚期帕金森病的两年随机对照研究。
Mov Disord. 2014 Sep;29(10):1273-80. doi: 10.1002/mds.25961. Epub 2014 Jul 10.
8
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.沙芬酰胺作为左旋多巴的附加疗法用于中晚期帕金森病波动型患者：016研究和SETTLE研究的事后分析
J Parkinsons Dis. 2016;6(1):165-73. doi: 10.3233/JPD-150700.
9
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.随机试验：添加沙芬酰胺治疗伴有运动波动的帕金森病患者的左旋多巴。
Mov Disord. 2014 Feb;29(2):229-37. doi: 10.1002/mds.25751. Epub 2013 Dec 9.
10
Real life evaluation of safinamide effectiveness in Parkinson's disease.真实世界中评估沙芬酰胺在帕金森病中的疗效。
Neurol Sci. 2018 Apr;39(4):733-739. doi: 10.1007/s10072-018-3272-y. Epub 2018 Feb 13.
引用本文的文献
1
The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease: Analysis of a Japanese Phase 2/3 Study.沙芬酰胺辅助治疗对帕金森病患者抑郁和冷漠的影响：一项日本2/3期研究的分析
Front Neurol. 2022 Feb 7;12:752632. doi: 10.3389/fneur.2021.752632. eCollection 2021.
Zotero 插件